Makes revisions relating to reproductive health care. (BDR 40-24)
SB217 makes broad changes to Nevada law concerning assisted reproduction, fertility treatment, and pregnancy-related insurance enrollment. The bill creates a new set of legal protections for assisted reproduction, including a prohibition on governmental entities substantially burdening access to assisted reproduction, related drugs and devices, information about assisted reproduction, or a person’s control over reproductive genetic material unless the government can satisfy a strict compelling-interest/least-restrictive-means test. It also authorizes lawsuits and defenses based on such burdens, allows the Attorney General to seek injunctions, and provides immunity from civil, criminal, and administrative liability for people and entities involved in assisted reproduction, subject to exceptions for independent wrongdoing such as negligence.
The bill also states that a fertilized egg or embryo before implantation is not a person, unborn child, minor child, or natural person for purposes of Nevada law. In addition, it requires many categories of health coverage to offer a special enrollment period for a person confirmed pregnant, and it expands coverage requirements for infertility diagnosis and treatment and for fertility preservation services. Those coverage mandates apply to group health plans, insurers, hospital and medical services corporations, health maintenance organizations, managed care organizations, and certain public programs, with different effective dates and some carve-outs for small employers, cafeteria plans, religiously affiliated entities, and certain Medicaid-managed care arrangements until later dates.
SB217 would significantly alter Nevada statutes governing health care, insurance, labor, Medicaid, and the legal status of embryos. It adds new provisions to the state’s patient-rights framework and amends multiple insurance chapters to require pregnancy special enrollment and fertility-related coverage, while also limiting cost-sharing, prior authorization, waiting periods, and other utilization controls for those benefits. The bill further directs the Department of Health and Human Services and the Division of Health Care Financing and Policy to seek federal approval and implement Medicaid fertility coverage beginning in 2027, and it authorizes enforcement actions and insurance regulatory penalties for noncompliance. It also amends labor law to enforce the pregnancy enrollment requirement for employers offering health benefits.
The available voting history suggests the bill had majority support in both chambers, passing the Senate 15-5 and the Assembly 27-15. The broad scope of the measure and its focus on reproductive health care indicate strong support from sponsors and supporters for expanding access to fertility care and protecting assisted reproduction. At the same time, the recorded opposition in both chambers shows that the bill was not unanimous and likely drew concern from members skeptical of its legal and fiscal implications, especially its treatment of embryos, its insurance mandates, and its limits on government regulation.
The main points of contention are likely to have been the bill’s declaration that a pre-implantation embryo is not a legal person, its restriction on governmental regulation of assisted reproduction, and the breadth of the insurance mandates. Opponents may have objected to the strict scrutiny-style standard for laws affecting assisted reproduction, the immunity provisions for providers and manufacturers, and the potential cost impact on insurers, employers, local governments, and public programs. Religious exemptions and the delayed application to Medicaid-managed care and Medicaid coverage likely reflect attempts to address some of those concerns, while supporters likely viewed the bill as necessary to protect reproductive autonomy and ensure access to fertility treatment and preservation.